Miles Congreve

Biography

 Miles obtained a BSc in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University, before joining Glaxo in 1993. In 2001 he joined Astex Technology (now Astex Therapeutics, part of Otsuka) to establish the chemistry team and to develop and validate fragment-based drug discovery as a new approach to structure-based drug design and lead identification. He was promoted to Director of Chemistry in 2006. The platform delivered success against a broad range of projects (collaborative and in-house), including at least six clinical candidates. Miles is a co-inventor of Ribociclib (Kisqali®) which recently received FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer. He joined Heptares in 2008 as Head of Chemistry and now has responsibility for the overall Discovery team. Miles is co-author of over 90 publications and co-inventor on more than 50 patent filings. Miles received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and Medicinal Chemistry Sector, in recognition of his contribution to GPCR drug discovery.

Research Interest

 biological chemistry